<DOC>
	<DOCNO>NCT01934712</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial evaluate pharmacokinetic ( exposure trial drug body ) pharmacodynamic ( effect trial drug body ) property FIAsp ( faster-acting insulin aspart ) currently market insulin aspart ( NovoRapidÂ® ) Japanese subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetic Properties FIAsp Japanese Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) 12 month long Body mass index ( BMI ) 18.528.0 kg/m^2 ( inclusive ) Subject donate blood plasma past month 500 mL within 3 month prior screen Smoker ( define subject smoking least one cigarette , cigar pipe daily ) Not able willing refrain smoking use nicotine substitute product inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>